Related Experiment Video
Updated: Feb 12, 2026

Development of New Therapeutic Applications Using Microfluidics
Published on: October 1, 2007
Medication development in opioid addiction: Meaningful clinical end points
Nora D Volkow1, Janet Woodcock2, Wilson M Compton3
1National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA. nvolkow@nida.nih.gov.
Abstract:
The FDA's "abstinence" outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.
More Related Videos
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Receptors: Overview
Drug Abuse and Addiction: Pharmacological Phenomena
Opioid Analgesics: Morphine and Other Natural Cogeners
Inhaled Medications
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

